Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
BPC-157, Synthetic pentadecapeptide
A 15 amino acid peptide fragment based on a sequence in human gastric juice, studied extensively for tissue repair and angiogenic signaling in preclinical models.
In animal studies, BPC-157 is thought to switch on the body's blood vessel growth signaling, which is how researchers believe it speeds tissue repair.
Fibroblast outgrowth, survival & migration
VEGFR2-Akt-eNOS signaling & vessel density
Transected/detached muscle reattachment
Gut lining protection & repair signaling
Dopaminergic / serotonergic signaling
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Chang CH, et al.
BPC-157 accelerated tendon explant outgrowth, increased tendon fibroblast survival under oxidative (H₂O₂) stress, and increased cell migration in a dose dependent manner in vitro.
Hsieh MJ, et al.
BPC-157 promoted VEGFR2 internalization and activated the VEGFR2-Akt-eNOS pathway, increasing vessel density and accelerating blood flow recovery in rat hind limb ischemia.
Claimed for tendon/ligament/muscle healing and gut repair. As of 2026 it has not completed any registered Phase II or III human trial, only a few small pilots exist (intra articular knee pain, interstitial cystitis, IV safety/PK). Essentially all efficacy data is rodent.
Human safety is genuinely unknown: no PK characterization and unknown immunogenicity for a non naturally occurring peptide. A theoretical oncologic concern is that the same VEGF/angiogenesis pathway that aids healing could feed an existing tumor. Anecdotal reports include nausea, dizziness, and injection site reactions.
Active or suspected malignancy; pregnancy; anyone unable to verify product quality.
Not FDA approved. Placed in FDA Category 2 (Sept 2023) and removed in April 2026 (nomination withdrawn), a grey zone that does NOT authorize compounding. Scheduled for PCAC review July 23, 2026 (ulcerative colitis). WADA prohibited (S0, explicitly named).
Subcutaneous or oral in protocols; reportedly stable in gastric juice. Half life in humans is uncharacterized.
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.
Cerovecki T, et al.
Across intraperitoneal, oral, and topical routes, BPC-157 produced consistent functional, biomechanical, macroscopic, and histological improvement in transected medial collateral ligament healing over 90 days.
Staresinic M, et al.
BPC-157 improved Achilles tendon recovery biomechanically (load to failure, elasticity), functionally, and histologically, and directly stimulated tendocyte growth in vitro.
Vasireddi N, et al.
Of 544 records screened, 36 studies met criteria, 35 preclinical and only 1 clinical, underscoring promising animal data alongside minimal human evidence.